Plain-English translation of NCT07223814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a new medication called , when combined with standard chemotherapy, can help treat a specific type of blood cancer called acute myeloid leukemia (AML). The medication works by blocking proteins that help leukemia cells survive, causing them to die. About 875 patients will receive either the medication or a placebo (a dummy pill) along with their standard chemotherapy to see which group does better.
Currently, standard chemotherapy is the main treatment for this type of blood cancer, but doctors are looking for ways to improve survival and outcomes. This medication targets the genetic changes that fuel this specific type of leukemia, so researchers believe adding it to chemotherapy could be more effective than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
You will receive intensive chemotherapy combined with either the new medication or a placebo over several months (induction and consolidation phases). After that, you'll continue with either the medication or placebo as maintenance treatment until your cancer stops responding, you experience unacceptable side effects, or your doctor stops the treatment. You'll be followed for up to 4 years total, with regular clinic visits and blood tests to monitor your response and safety.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States